Bharat Biotech launches Nucelion Therapeutics to drive cell and gene therapy innovation in India
The launch reflects the pharmaceutical sector’s growing focus on biological innovation
By - Newsmeter Network
Representational Image
Hyderabad: Bharat Biotech International Ltd has announced the formal launch of Nucelion Therapeutics Pvt Ltd, marking its entry into cell and gene therapies aimed at curing cancers, autoimmune disorders, and rare genetic diseases.
Advancing Next-Gen Therapies
Nucelion is positioned to support global life science innovators by offering comprehensive process development and manufacturing solutions for advanced therapies addressing complex conditions such as cancer, autoimmune, and rare genetic disorders.
The launch reflects the pharmaceutical sector’s growing focus on biological innovation, where CGTs are becoming key growth drivers. The objective is to transition autologous, allogeneic, and in vivo cell therapies from specialized research programs to scalable platforms, expanding their role in oncology, immunology, and regenerative medicine.
Genome Valley Hub
Located in Hyderabad’s Genome Valley, the CRDMO has established a 30,000-square-foot, purpose-built GMP facility designed to handle the development and manufacturing of:
Plasmids
Viral and non-viral vectors
Cell therapies
Aseptic fill and finish
Nucelion will deliver fully integrated services spanning early-stage clinical development to large-scale commercial manufacturing, maintaining strict adherence to FDA and EMA regulatory standards.
Visionary Leadership and Global Standards
Dr. Krishna Ella, Non-Executive Director of Nucelion Therapeutics, highlighted the initiative’s strategic direction: “The future of pharmaceutical innovation is biological, with CGTs as the core. Our mission is to embed advanced therapy platforms within India’s healthcare system to ensure equitable access to treatments for complex and rare diseases.”
Dr. Raghu Malapaka, Chief Business Officer, added: “Nucelion provides end-to-end solutions from clinical through commercial scale while ensuring compliance with international regulations (FDA, EMA). Our services include the development and production of plasmid DNA, viral vectors, and both autologous and allogeneic cell therapies.”
